A liver transplant candidate who is CMV serostatus positive and is subjected to calcineurin inhibitor such as tacrolimus post transplant may increase risk of CMV disease, and may promote tumor progression in some. We ...A liver transplant candidate who is CMV serostatus positive and is subjected to calcineurin inhibitor such as tacrolimus post transplant may increase risk of CMV disease, and may promote tumor progression in some. We report a case of a late localized CMV disease manifesting as oesophagitis after 7 years post orthotopic liver transplantation complicated with an aggressive scalp squamous cell carcinoma which recurred despite wide local excision procedure. Hence it is crucial to modulate the patient’s risk factors for tumor progression without compromising the patient to graft rejection.展开更多
文摘A liver transplant candidate who is CMV serostatus positive and is subjected to calcineurin inhibitor such as tacrolimus post transplant may increase risk of CMV disease, and may promote tumor progression in some. We report a case of a late localized CMV disease manifesting as oesophagitis after 7 years post orthotopic liver transplantation complicated with an aggressive scalp squamous cell carcinoma which recurred despite wide local excision procedure. Hence it is crucial to modulate the patient’s risk factors for tumor progression without compromising the patient to graft rejection.
